Slide 1: NeoGenomics Investor Presentation August 2021
NeoGenomics Investor Presentation August 2021 1 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 This presentation has been prepared by NeoGenomics, Inc. (“we,” ”us,” “our,” “NeoGenomics” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale
Slide 3: Our Common Purpose, Vision and Values
We save lives by improving patient care. By providing uncompromising quality, exceptional service and innovative solutions, we are becoming the world’s leading cancer testing and information company. Quality, integrity, accountability, teamwork, innovation. NeoGenomics We are Focused and Genuine Our
Slide 4: Snapshot: FY 2020 Key Figures
4 FY 2020 Key Figures** Revenue: $444MM Revenue Growth: 9% Core Clinical Test Volume: 976,069 Unique Patients Tested: >435,000 Adjusted EBITDA: $35MM FY 2020 Revenue Mix* Snapshot One Lab. Vital Answers. Transforming Care for Cancer Patients • Leading oncology diagnostic company with diversified, “O
Slide 5: Clinical, Pharma Services and Informatics Divisions
Informatics Division One Lab. Vital Answers. 5 Leading oncology diagnostics company, designed to provide innovative diagnostic and data solutions that bridge oncologists, pathologists, and therapeutic development • Leading oncology reference lab market share for oncologists, pathologists and hospita
Slide 6: Inivata Review: Leading Liquid Biopsy Platform
Inivata Review: One Leading Liquid Biopsy Platform with Multiple Applications | L I Q U I D B I O P S Y P L AT F O R M Specifically designed for liquid biopsy Optimized for high sensitivity Robust customizable approach R&D Capabilities Regulatory Capabilities Reimbursement Capabilities • 37 gene pan
Slide 7: Locations across continents
13 locations across 3 continents Leading provider of oncology testing and global oncology research services NeoGenomics 2 3 4 5 9 10 11 12 13 6 7 8 1 7 Carlsbad, California Houston, Texas La Jolla, California Fort Myers, Florida Tampa, Florida Atlanta, Georgia Nashville, Tennessee RTP, North Carolin
Slide 8: Oncology Testing Market Tailwinds
Oncology Testing Market Tailwinds Estimated 6% to 8% annual market growth with upside potential Demographics − An aging population is resulting in higher cancer incidence − Increased cancer survival rates leading to more follow-on testing Precision Medicine & Drug Development − Proliferation and com
Slide 9: Market Tailwinds: Demographics
Market Tailwinds: Demographics An aging population is leading to higher cancer incidence with new precision therapies allowing people to live longer with cancer Source: National Cancer Institute 9 2030 22.2 Million Cancer Survivors 10 years 31% Increase The number of cancer survivors is projected to
Slide 10: Market Tailwinds: Precision Medicine
Source: IQVIA Institute. June 2020 10 2007 2012 2016 2019 70 47 25 17 A dramatic increase in approved precision oncology medicines is driving the need for associated biomarker testing. Market Tailwinds: Precision Medicine Oncology therapies with required or recommended biomarker testing
Slide 11: Market Tailwinds: Drug Development
Market Tailwinds: Drug Development Diagnostic testing is critical as additional drugs gain approval Source: IQVIA Pipeline Intelligence, Dec 2018; IQVIA Institute, May 2019 11 New oncology molecules are being developed at a record pace. The late phase targeted therapy oncology pipeline increased 100
Slide 12: We Look to Grow at Twice the Market Rate
We Look to Grow at Twice the Market Rate 12 Significant Company-Specific Growth Drivers 1 The most comprehensive test menu in oncology Dx – including advanced NGS capabilities such as liquid biopsy 2 Uncompromising customer service with exceptional turn around time on testing 3 4 5 Over 120 MDs and
Slide 13: History of Organic and Inorganic Success
$40 $56 $63 $79 $88 $203 $210 $242 $361 $382 76k 112k 136k 176k 223k 563k 657k 750k 988k 976k 0 200 400 600 800 1,000 1,200 0 50 100 150 200 250 300 350 400 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Clinical Testing Revenue ($MM) Clinical Tests Performed Clinical Testing Annual Revenue / Cor
Slide 14: Our Focus Is The Community Setting
Our Focus Is The Community Setting We bring state-of-the-art oncology testing to the masses 14 NeoGenomics works with >4,400 hospitals, institutions and oncology offices, most in the community setting, to ensure all patients can benefit from high-quality diagnostic tests to support Precision Medicin
Slide 15: Comprehensive Oncology Test Menu
Comprehensive Oncology Test Menu A low Beta approach to a massive high growth end market 15 • Consultation pathology • Immunochemistry • Immunohistochemistry • Digital imaging • Automated quantitative IHC • Global and tech-only service • 10-color flow • MRD detection • Global and tech-only service •
Slide 16: A Differentiated Approach To NGS Testing
Targeted Profiles Broad Based Profiles Liquid Biopsy 26 NeoTYPE® targeted profiles • Multi-Modal • Only appropriate biomarkers • 19 Solid Tumor Profiles • 7 Heme Profiles 17 Targeted RNA Fusion Profiles • High capacity workflow • Only appropriate biomarkers • Detection of novel fusions Solid Tumor •
Slide 17: We Are Focused on The Customer
We Are Focused on The Customer NOTES: 1,055 respondents 17 Best-in-class net promoter score Q4 2020 Clinical Client Survey How likely is it that you would recommend this company to a friend or colleague? 0 1 2 3 4 5 6 7 8 9 10 Not at all likely Neutral Extremely likely Detractor Passive Promoter 7%
Slide 18: Competing Through Focus, Scale and Scope
Clinical Reference Labs with Oncology Divisions Niche Oncology Players High R&D investment and limited test menus 18 Diversified Focus Leading Share in U.S. Clinical Oncology Market Comprehensive, multi-modality “One Lab” position Large and advanced somatic cancer test menu Significant reach into al
Slide 19: Our Ability to Profitably Innovate Enables Sustainable Growth
Our Ability to Profitably Innovate Enables Sustainable Growth 19 Core Clinical Business • Growing volumes >10%* • Self-funding innovation Three important growth areas in the business today were enabled by leveraging the power of our growing core clinical engine. These initiatives could represent nea
Slide 20: Rapidly Growing Pharma Services Business
Rapidly Growing Pharma Services Business The Company defines Dormant Projects as projects with no activity for 12 months or longer that have not officially been cancelled by the Sponsor *Amount includes a contribution from acquired Inivata backlog 20 $13.0 $16.7 $19.3 $19.0 $20.3 $40.5 $34.9 $48.0 $
Slide 21: Uniquely Positioned: Pharma Services
Uniquely Positioned: Pharma Services Factors driving pharma services success in the oncology marketplace 21 $42M* new signed contracts recorded in Q2 of 2021 Synergies with Clinical & Informatics More than 40 Active Companion Diagnostic Projects Ongoing A Record $238M backlog exiting Q2 of 2021 Comp
Slide 22: Informatics
Informatics Patient-focused. Data driven. 22 Our information platform includes one of the largest cancer testing databases, covering the complete spectrum of oncology testing modalities for over 1.6 million patients. >1.6M patients tested 5 years historical data >4,400 clinical clients >435k patient
Slide 23: Informatics Primary offerings today
Informatics Primary offerings today 23 Diagnostic lab alerts and commercial analytics Clinical trial matching and provider outreach Trapelo Health Clinical Decision Support
Slide 24: Three Operating Divisions That Are Increasingly Synergistic
Three Operating Divisions That Are Increasingly Synergistic 24 Innovation and scale has made our three divisions increasingly synergistic over time creating a flywheel effect. Data-driven insights to support drug discovery, clinical trials & commercial activity Clinical Decision Support Sponsored te
Slide 25: Leading Oncology Diagnostics Company Guided By Science
Leading Oncology Diagnostics Company 25 Guided By Science And Passion For Patient Care We are a leader in the field of diagnostic testing with a significant share of patient test volume in the US Our extensive patient database allows us to optimize the pairing of patients with clinical trials We act
Slide 26: One Lab. Vital Answers.
One Lab. Vital Answers. Transforming Care for Cancer Patients.
Slide 27: Appendix
Appendix
Slide 28: Experience and Scale Matter
28 Experience and Scale Matter >435,000 patients per year ~1 million cancer-related tests per year >4,400 hospital, institution and oncology office clients 620+ cancer tests ready for order >50,000 Clinical Next Gen Sequencing tests per year 336 Biomarker solid tumor discovery panel 26 targeted NeoT
Slide 29: Estimated Annual Market Opportunity ~$15Bn+
Estimated Annual Market Opportunity ~$15Bn+ 284 249 236 159 106 84 76 67 60 44 Br ea st Pr os ta te Lu ng Co lo re ct al M el an om a Bl ad de r Ki dn ey U te ru s Pa nc re as Th yr oi d Es t. 20 21 In ci de nc e (K ) More than 1.3mm new patients per year may be addressable by MRD across the top 10
Slide 30: RaDaR Review: Sensitivity Matters
RaDaR Review: Sensitivity Matters RaDaR is Designed to Directly Address the Key Needs in the MRD Market • Inherent high sensitivity of InVision platform vs competitor technology • Very deep sequencing enables higher sensitivity • Personalized assay targeting 48 variants known to be present in the ca
Slide 31: The RaDaR Assay Shows Excellent Sensitivity
The RaDaR Assay Shows Excellent Sensitivity 31 RaDaR Company A Company B Lung Cancer Study LUCID, AACR 2020 TRACERx, Nature 2017 TRACERx, AACR 2020 Variants tracked 48 12 – 30 50 – 200 Cohort size 90 patients 96 patients 88 patients Median lead time from ctDNA to clinical recurrence 203 days 70 days
Slide 32: Balance Sheet, June 30, 2021
Balance Sheet, June 30, 2021 (unaudited, in thousands) 32 June 30, 2021 (unaudited) December 31, 2020 ASSETS Cash and cash equivalents $ 368,796 $ 228,713 Marketable securities, at fair value 202,950 67,546 Accounts receivable, net 106,284 106,843 Inventories 21,384 29,526 Prepaid assets 13,959 11,5
Slide 33: Income Statement, June 30, 2021
Income Statement, June 30, 2021 (unaudited, in thousands) 33 Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 NET REVENUE: Clinical Services $ 101,405 $ 73,884 $ 197,892 $ 166,866 Pharma Services 20,319 13,093 39,365 26,141 Total revenue 121,724 86,977 237,257 193,007 COST O
Slide 34: Statements of Cash Flows, June 30, 2021
Statements of Cash Flows, June 30, 2021 (unaudited, in thousands) 34 Six Months Ended June 30, 2021 2020 CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) $ 53,759 $ (13,802) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation 13,629 12,177 Amor
Slide 35: Segment Results, June 30, 2021
Segment Results, June 30, 2021 (unaudited, in thousands) 35 (17) Clinical cost of revenue for the three months ended June 30, 2021 includes $0.7 million amortization of acquired intangible assets. Clinical cost of revenue for the six months ended June 30, 2021 includes $0.7 million amortization of a
Slide 36: Segment Results continued, June 30, 2021
Segment Results continued, June 30, 2021 (unaudited, in thousands) 36 (18) Clinical tests exclude requisitions, tests, revenue and costs of revenue for Pharma Services, COVID-19 PCR tests and the amortization for acquired intangible assets. Three Months Ended June 30, Six Months Ended June 30, 2021
Slide 37: Adjusted EBITDA, June 30, 2021
Adjusted EBITDA, June 30, 2021 (unaudited, in thousands) 37 Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Net income (loss) (GAAP) $ 75,873 $ (6,824) $ 53,759 $ (13,802) Adjustments to net income (loss): Interest expense, net 902 1,548 2,079 2,367 Income tax benefit (2,43